Takeda Pharmaceutical Co. Ltd. is bracing for “significant penetration of generic product” for its blockbuster multiple myeloma drug Velcade (bortezomib) in the US, particularly with the advent of the first such competitors in a subcutaneous formulation.
The proteasome inhibitor generated global sales of JPY137.3bn ($1.24bn) - including JPY113.7bn in the US - in the fiscal year...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
